Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Non-Current Liabilities (2016 - 2021)

Historic Total Non-Current Liabilities for OptimizeRx (OPRX) over the last 13 years, with Q3 2021 value amounting to $260614.0.

  • OptimizeRx's Total Non-Current Liabilities fell 2692.07% to $260614.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $260614.0, marking a year-over-year decrease of 2692.07%. This contributed to the annual value of $325533.0 for FY2020, which is 9425.74% down from last year.
  • Latest data reveals that OptimizeRx reported Total Non-Current Liabilities of $260614.0 as of Q3 2021, which was down 2692.07% from $282934.0 recorded in Q2 2021.
  • OptimizeRx's Total Non-Current Liabilities' 5-year high stood at $5.7 million during Q4 2019, with a 5-year trough of $260614.0 in Q3 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $1.6 million (2017), whereas its average is $1.6 million.
  • In the last 5 years, OptimizeRx's Total Non-Current Liabilities surged by 51212.19% in 2017 and then tumbled by 9425.74% in 2020.
  • Over the past 5 years, OptimizeRx's Total Non-Current Liabilities (Quarter) stood at $2.3 million in 2017, then grew by 4.8% to $2.4 million in 2018, then surged by 139.69% to $5.7 million in 2019, then plummeted by 94.26% to $325533.0 in 2020, then fell by 19.94% to $260614.0 in 2021.
  • Its last three reported values are $260614.0 in Q3 2021, $282934.0 for Q2 2021, and $305039.0 during Q1 2021.